We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




The OncoMasTR Test Accurately Identifies Risk of Breast Cancer Recurrence

By LabMedica International staff writers
Posted on 29 Jun 2021
A recent paper confirmed that the Oncomark (Dublin, Ireland) OncoMasTR test can accurately identify the risk for disease recurrence in patients with hormone receptor–positive HER2-negative early-stage breast cancer.

OncoMasTR is a multi-parameter prognostic test for ER-positive, HER2-negative early stage breast cancer patients with up to three involved lymph nodes. More...
The OncoMasTR RT-qPCR test measures the expression of three prognostic genes (plus three reference genes) and estimates the probability of distant recurrence for breast cancer patients, thereby aiding clinicians in determining the best treatment options for their patients and avoiding the costs and severe side-effects from unwarranted chemotherapy, ultimately improving the quality of life of the patient.

Investigators at University College Dublin (Ireland) compared the efficacy of the OncoMasTR test to seven other commercially available assays. Among these was the Exact Sciences (Madison, WI, USA) Oncotype DX Breast Recurrence Score Test, which analyzes the activity of 21 genes that can influence how likely a cancer is to grow and respond to treatment.

For this study, the investigators analyzed tissue samples from 404 Irish women who were enrolled in the Trial Assigning Individualized Options for Treatment [Rx]. Gene expression measured via RT-qPCR was used to calculate the OncoMasTR Molecular Score (OMm) and a composite risk score, the OncoMasTR Risk Score (OM).

Results revealed that OMm and OM were more prognostic for distant recurrence-free survival and provided significant additional prognostic information to all other assessment tools/factors assessed. In addition, the OM correctly classified more patients with distant recurrences into the high-risk category than other risk classification tools. Similar results were observed for invasive disease-free survival.

Senior author Dr. William Gallagher, professor of cancer biology at University College Dublin, said, "This key clinical validation study showed that the OncoMasTR test has truly excellent performance in terms of predicting outcome of these patients, with improved performance versus the currently used approaches in the clinic. This may help clinicians to optimize treatment decisions."

The OncoMasTR paper was published in the June 2, 2021, online edition of European Journal of Cancer.

Related Links:
Oncomark
University College Dublin
Exact Sciences



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PSA Assay
CanAg PSA EIA
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.